Objectives Stratifi ed management for low back pain according to patients' prognosis and matched care pathways has been shown to be an effective treatment approach in primary care. The aim of this within-trial study was to determine the economic implications of providing such an intervention, compared with nonstratifi ed current best practice, within specifi c risk-defi ned subgroups (low-risk, medium-risk and high-risk). Methods Within a cost-utility framework, the base-case analysis estimated the incremental healthcare cost per additional quality-adjusted life year (QALY), using the EQ-5D to generate QALYs, for each risk-defi ned subgroup. Uncertainty was explored with cost-utility planes and acceptability curves. Sensitivity analyses were performed to consider alternative costing methodologies, including the assessment of societal loss relating to work absence and the incorporation of generic (ie, non-back pain) healthcare utilisation. Results The stratifi ed management approach was a cost-effective treatment strategy compared with current best practice within each risk-defi ned subgroup, exhibiting dominance (greater benefi t and lower costs) for medium-risk patients and acceptable incremental cost to utility ratios for low-risk and high-risk patients. The likelihood that stratifi ed care provides a cost-effective use of resources exceeds 90% at willingness-to-pay thresholds of £4000 (≈ 4500; $6500) per additional QALY for the medium-risk and high-risk groups. Patients receiving stratifi ed care also reported fewer back pain-related days off work in all three subgroups. Conclusions Compared with current best practice, stratifi ed primary care management for low back pain provides a highly cost-effective use of resources across all risk-defi ned subgroups.
INTRODUCTION
The health, social and economic burden of low back pain is well established. [1] [2] [3] In the UK, annual total costs attributable to low back pain have been estimated at £12.3 billion; £1.6 billion for direct healthcare resources, £1.6 billion related to informal care and £9.1 billion through production loss (indirect costs) due to morbidity. 1 Despite adopting different methodologies, evidence from North America and Europe has consistently observed that the provision of care by primary care practitioners and physiotherapists contributes 25%-30% of direct healthcare costs and indirect costs represent the majority of overall costs. 1 4 EXTENDED REPORT Exploring the cost-utility of stratifi ed primary care management for low back pain compared with current best practice within risk-defi ned subgroups David G T Whitehurst, 1,2,3 Stirling Bryan, 1,2 Martyn Lewis, 3 Jonathan Hill, 3 Elaine M Hay 3 Despite a number of high-quality randomised controlled trials in recent years, [5] [6] [7] [8] [9] fundamental questions about which patients will respond best to specifi c interventions remain unanswered, although clear support exists for active intervention over 'no treatment'. 10 11 To acknowledge the accepted concept of low back pain patient heterogeneity, a recent study found that a novel stratifi ed primary care management approach based on the use of a prognostic screening tool (to allocate patients into one of three risk-defi ned groups) combined with matched treatment pathways improves long-term disability compared with current best practice. 12 13 Previous economic evaluations have demonstrated the cost-effectiveness of interventions that include manual therapy techniques compared with active comparator groups, [14] [15] [16] while group-based cognitive behavioural treatments 9 and acupuncture care 17 have also provided acceptable cost-effectiveness estimates. However, the consistency of small clinical differences between treatment groups and the paucity of cost-effectiveness evidence means that a degree of uncertainty exists regarding the value of low back pain treatments. 18 Evidence for the overall cost-effectiveness of a stratifi ed primary care management approach for low back pain has been reported elsewhere. 13 This study provides new data from a prespecifi ed subgroup analysis, reporting the fi rst detailed assessment of costeffectiveness within risk-defi ned subgroups resulting from a stratifi ed treatment approach.
METHODS

Trial design and interventions
Full details of the trial design, rationale, participants and interventions have been reported elsewhere; 12 13 online supplementary appendix S1 provides brief details of the screening tool used to stratify patients and the content of the interventions. Adults aged 18 years and over with low back pain of any episode duration consulting in 1 of 10 general practices in North Staffordshire (UK) were invited to receive initial assessment and treatment in a physiotherapy-led back pain referral clinic. In the clinic, an administrator telephoned a remote trials unit that used random computer sequence selection of stratifi ed blocks with a 2:1 ratio to randomly assign participants to receive stratifi ed primary care management (intervention, n=568) or current best practice (in line with standard physiotherapy; control group, n=283). The controlled trial was powered to explore two primary objectives: (1) to investigate the overall effectiveness of stratifi ed primary care back pain management with matched treatment pathways against non-stratifi ed current best practice and (2) to determine whether low-risk patients had non-inferior outcomes, and medium-risk and high-risk patients had superior outcomes when receiving the stratifi ed care intervention. This study reports the economic consequences of stratifi ed care for each risk-defi ned subgroup within a cost-utility framework.
Economic study design
The base-case economic analysis was performed from a healthcare perspective, incorporating UK National Health Service (NHS) and private back pain-related healthcare resources utilised during the 12-month follow-up period (further details provided below). In line with the clinical evaluation, the provision of estimates for the cost-effectiveness of stratifi ed primary care management within each risk-defi ned subgroup was a prespecifi ed analysis. 12 13 However, differences in the methodological approaches and reporting techniques of the controlled trial and economic evaluation are a refl ection of the different research objectives and analytical paradigms of clinical and economic research. 19 20 
Data: measures and collection
Details of the numbers of study-related physiotherapy sessions attended by each participant were collected through case report forms and an audit of clinical notes for the participating physiotherapy services. All other outcome data included in the analysis were collected via self-report postal questionnaires. 12 
Health outcomes
The EQ-5D was used to measure preference-based healthrelated quality of life at baseline, 4-months and 12-months. 21 For each EQ-5D response, utility scores were generated using the 'York A1 tariff'; preference data for this tariff were elicited from a representative sample of the UK adult population, providing index scores within a range of −0.594 (the lowest level on each dimension) to 1.000 (the highest level on each dimension). 22 Negative values indicate that some health states are valued worse than death. Using area-under-the-curve analysis, assuming linear interpolation between consecutive timepoints, EQ-5D responses were used to generate quality-adjusted life years (QALYs). The QALY represents the benefi t of a healthcare intervention in terms of time spent in a series of qualityweighted health states. In this study, the maximum number of QALYs was equal to 1, with QALY scores below 1 refl ecting less than perfect health.
Healthcare resource use and unit costs
The 12-month follow-up questionnaire collected resource use data for a range of services: primary healthcare consultations (general practitioners and practice nurses), consultations with other healthcare professionals (eg, hospital consultants, physiotherapists, acupuncturists), hospital-based procedures (diagnostic tests, epidural injections, inpatient episodes), prescribed medication, and patient borne out-of-pocket expenditure on treatments and/or aids. Where appropriate, patients were required to distinguish between UK NHS and private provision. Details of consultations with healthcare practitioners for health reasons other than low back pain were also collected. Unit costs used in the analysis are reported in online supplementary table S1, expressed as UK averages in 2008/09 prices. [23] [24] [25] [26] [27] [28] [29] Work-related outcomes To assess the economic consequences of the stratifi ed management intervention beyond healthcare resources, self-reported details of participants' employment status were collected at baseline and 12 months. For those in paid employment, the selfreport questionnaires requested further details of typical work activities and periods of back pain-related work absence. Costs were assigned using the human capital approach; 30 self-reported days of work absence were multiplied by respondent-specifi c wage estimates identifi ed from annual earnings data and UK Standard Occupational Classifi cation coding. 29 31 
Statistical analysis
Analysis was performed according to the intention-to-treat principle, with imputation techniques adopted to address the issue of incomplete data. For the returned 12-month questionnaires, a small number of missing resource use values (<3%) were imputed using mean substitution based on the observed data for the respective resource category. Following this, multiple imputation was used to impute all missing values for the EQ-5D and total cost estimates for non-responders to the 12-month questionnaire. 32 Five estimates for each missing value were generated using simulation based on a multivariate normal model. The imputed observation is the arithmetic mean of the fi ve estimated values, with reported SDs and CI adjusted to incorporate the additional 'between-imputation' variance. 32 Within each risk-defi ned subgroup, the analytic comparison focused on the joint estimation of incremental costs and incremental QALYs (with increments calculated as the intervention group value minus the control group value). 19, 20 The primary unit of outcome was the incremental cost per-QALY (incremental cost divided by incremental QALY), a ratio measure that provides an estimate of the cost required to achieve one additional QALY. Costs relating to periods of work absence were analysed separately, without incorporation into the incremental ratio. For the estimation of incremental QALYs, between-group imbalances were accounted for through multiple regressionbased adjustment for age, gender, duration of pain at baseline, and baseline scores on the primary outcome measure (RolandMorris Disability Questionnaire (RMDQ) 33 ) and EQ-5D. 34 Given the 12-month follow-up period of the trial no discounting was necessary.
Consideration of uncertainty around the incremental ratio using CI estimation is problematic, particularly with small denominator values. Within economic evaluation, the derivation of cost-utility planes and acceptability curves, through the application of bootstrap techniques, provides a graphical display (plane and curve) and quantifi cation (curve) of the level of uncertainty around ratio point estimates; 35 25 000 bootstrapped replications of incremental cost-utility pairs were used in the assessment of uncertainty (5000 for each imputed data set).
To explore variation in disaggregated outcomes (costs, QALYs and EQ-5D scores), CI estimation was performed. This is a secondary consideration in economic evaluation due to the focus on joint estimation of costs and effects rather than arbitrary rules of conventional statistical inference. 19 Given the level of skewness typically observed for cost data, CI were generated using parametric methods and bias-corrected and accelerated bootstrapping. 36 Statistical analysis was performed using SPSS for Windows V.17 and STATA V.11.
Sensitivity analysis
Sensitivity analyses were performed to explore variation in methodological approaches: (1) analysis of healthcare resources funded by the NHS only, in line with recommendations from the National Institute for Health and Clinical Excellence in the UK; 37 (2) the incorporation of non-back pain-related consultations with healthcare professionals; (3) a complete case analysis, where inclusion required a valid EQ-5D response at each data collection stage and complete healthcare resource use data at 12-month follow-up; and (4) consideration of variation in the unit cost of private healthcare. The fi nal sensitivity analysis involved simultaneously multiplying the unit costs of private healthcare by a price premium ranging from one (private costs equal NHS costs) to three (private costs are three times the unit cost of the NHS equivalent).
RESULTS
The clinical trial identifi ed signifi cant overall reductions in back pain disability (RMDQ) at 4 and 12 months using the stratifi ed management approach compared with current best practice. Briefl y, there were signifi cant between-group differences in RMDQ adjusted mean change scores for medium-risk patients at 4 and 12 months, and high-risk patients at 4 months. Low-risk patients had non-inferior outcomes compared with controls at both time-points. Baseline characteristics were similar across treatment groups (within each stratifi ed risk group). 13 
Observed responses and presentation of data
Cost estimates were derived for 567 (67%) responders at 12 months. For the EQ-5D, complete data were provided by 458 (54%) participants; time-point specifi c response rates were 99% (baseline), 73% (4 months) and 62% (12 months). The numbers of physiotherapy sessions resulting from the study back pain clinic were available for all participants. Baseline gender and back pain disability (RMDQ) were similar between 12-month responders and those lost to follow-up, although non-responders were signifi cantly younger. 12 Following the multiple imputation procedure, all 851 participants were included in the base-case analysis.
For each risk-defi ned subgroup, disaggregated back painrelated healthcare cost data are reported in table 1 for the 12-month responders; corresponding resource use data are provided in online supplementary table S2. Total cost estimates for 'intervention' and 'control' groups and the difference between treatment groups are also reported for each risk-group analysis. Quality of life data (EQ-5D and QALY scores) are provided in table 2.
Estimation of cost-utility
Point estimates of incremental costs and incremental QALYs demonstrate the stratifi ed management approach to be costeffective in all three risk groups. Based on conventional willingness to pay thresholds for additional QALYs (approximately £20 000 per QALY), 38 the incremental cost to utility ratio of £463 (£26.41/0.057 QALYs) in the high-risk group demonstrates that the additional health benefi ts are worth the additional cost. For the medium-risk group, a dominant position was observed for the stratifi ed management intervention, that is, greater mean health benefi t (0.044 additional QALYs) achieved at a lower mean healthcare cost (−£52.72); a position of dominance negates the need to calculate an incremental cost to utility ratio. Finally, for the low-risk group, the intervention was associated with a lower mean healthcare cost (−£64.29) and a lower mean health benefi t (−0.001 QALYs). The incremental cost to utility ratio of £48707 (−£64.29/−0.001 QALYs (QALY estimate to three decimal places)) indicates that the cost savings of the lowrisk intervention are worth the negligible decrement in health or, alternatively, the incremental cost required to achieve the small health benefi t associated with the control group is too expensive.
Figures 1A-C presents cost-utility planes for each riskgroup analysis. The location of the 'swarm' of bootstrapped cost-utility pairs identifi es the nature of the uncertainty in the incremental cost and QALY estimates; cost savings but considerable uncertainty regarding health benefi t within the low-risk group (cost-utility pairs are straddling the southern quadrants, fi gure 1A), cost savings and increased effectiveness within the medium-risk group (the majority (93%) of cost-utility pairs are located within the south-east quadrant, fi gure 1B), and increased costs and benefi ts for high-risk patients (the majority (67%) of cost-utility pairs are located within the north-east quadrant, fi gure 1C). The cost-utility acceptability curve is presented in fi gure 2, with all three risk-group analyses presented on the same fi gure. The acceptability curve quantifi es the joint uncertainty in incremental costs and effects; to illustrate, if a decision maker is willing to pay £20 000 (≈€23 000; $32 000) for an additional QALY, 38 the stratifi ed management intervention is associated with probabilities exceeding 0.99 and 0.95 of providing better value for money compared with current best practice for the medium-risk and high-risk groups, respectively. For the low-risk group, the plateau around a probability of 0.50 refl ects the negligible difference in QALYs; the stratifi ed management intervention is identifi ed as the cost-effective treatment option at low willingness to pay levels due to the estimated cost savings.
Work-related outcomes
Results regarding paid employment, work status and back painrelated work absence are reported in table 3. Stratifi ed primary care was associated with fewer self-reported days off work within each risk-defi ned subgroup and societal cost savings were observed in the low-risk and medium-risk groups.
Sensitivity analysis
For each risk-defi ned subgroup, the same policy implications of the base-case analysis were replicated in all sensitivity analyses that explored variation in the adopted costing methodology, that is, a dominant position for the medium-risk group and acceptable incremental ratios for the low-risk and high-risk groups. Within the complete-case analysis, the stratifi ed management intervention was associated with lower costs and greater health benefi t compared with current best practice in the medium-risk and high-risk groups. Cost estimates for the sensitivity analyses are reported in online supplementary table S3; corresponding incremental QALY data are reported in table 2.
DISCUSSION
Primary care management of low back pain based on the use of a prognostic screening tool combined with matched treatment pathways is a cost-effective strategy compared with current best practice across all three risk-defi ned subgroups. Further support for the stratifi ed management approach was provided through the identifi cation of societal cost savings due to reductions in back pain-related work absence (in the low-risk and mediumrisk groups) and the robustness of results when exploring variation in methodological approaches. These results provide the fi rst report of risk group-specifi c cost-effectiveness fi ndings for such an approach in the primary care management of low back pain.
Our results are applicable to a particular group of patients and healthcare professionals and caution should be exercised when drawing comparisons with other literature. The health benefi ts (incremental QALYs) attributable to the stratifi ed intervention observed in the medium-risk (0.044) and high-risk (0.057) groups are larger than those previously reported in low back pain economic evaluations. 14-17 39 One UK-based study of group cognitive behavioural treatment compared with a single advisory consultation observed an incremental QALY score of 0.099, 9 although a contributory factor in the magnitude of the .08 (2 dp) Complete-case analysis ‡ Low-risk subgroup (n=115 in total) --−0.007 (−0.04 to 0.03) p=0.70 (2 dp) Medium-risk subgroup (n=220 in total) --0.022 (−0.02 to 0.07) p=0.35 (2 dp) High-risk subgroup (n=123 in total) --0.077 (−0.00 to 0.16) ¶ p=0.06 (2 dp)
*QALYs, quality-adjusted life years, dp, decimal places. †Difference=targeted intervention -control group. Reported CIs were generated using conventional parametric methods. ‡Incremental QALY estimates following multiple regression-based adjustment for age, gender, duration of pain at baseline, and baseline scores on the RMDQ and EQ-5D. For the complete case analysis, only the incremental QALY estimate is provided. §The true value of '0.00' is positive; the fi gure reported is rounded to 2 dp. ¶The true value of '0.00' is negative; the fi gure reported is rounded to 2 dp.
Figure 1 (A)
Cost-utility plane comparing the stratifi ed management approach ('intervention') to current best practice ('control') for the low-risk subgroup. (B) Cost-utility plane comparing the stratifi ed management approach ('intervention') to current best practice ('control') for the medium-risk subgroup. (C) Cost-utility plane comparing the stratifi ed management approach ('intervention') to current best practice ('control') for the high-risk subgroup. QALY, quality-adjusted life year.
Figure 2
Cost-utility acceptability curves for the three risk group comparisons of stratifi ed primary care management ('intervention') compared to current best practice. QALYs, quality-adjusted life years.
incremental estimate reported by Lamb and colleagues was an atypical decrement in quality of life within the control group over 12 months.
Strengths, limitations and unanswered questions
Economic evaluations should provide decision-makers with evidence regarding the joint estimation of mean costs and effects and the appropriate handling of uncertainty. 19 20 The strengths of our analysis lie in the adopted approaches, comprehensive assessment of multiple research questions and the disaggregated presentation of results. The positive results for the stratifi ed intervention across all three risk groups, the robustness of study fi ndings in the sensitivity analyses and the sizeable cost savings associated with fewer days off work suggest that alternative settings (eg, location) are unlikely to question the study fi ndings. In addition, medium-risk and high-risk patients receiving current best practice sought additional healthcare over the 12-month follow-up, beyond the study treatment sessions (eg, non-study physiotherapy), compared with those randomised to stratifi ed care, which provided no discernible health benefi ts. Currently, the clinical and/or cost-effectiveness of a stratifi ed management approach in different clinical scenarios, such as one led by general practitioners, is unknown. The resource use and work-related data collection methods may be regarded as a limitation. The collection of such data requires a balance between suffi cient coverage of relevant questions and preventing unnecessary burden to patients and researchers. A comprehensive range of resources were costed in the study but there were considered omissions, for example, travel costs associated with attending study clinic sessions were not included because the magnitude of the difference between groups was expected to be minimal. Although criticisms of selfreport resource use and work-related data are well established, 40 41 the method provides an effi cient approach to data collection in the absence of routine data sources and has been used extensively in trial-based evaluations. 9 16 17 In addition, data for the key driver of total cost estimates (ie, the study clinic sessions) were fully observed following an audit of physiotherapy service databases.
Missing data raise questions about the validity of study fi ndings. Response rates for the primary cost (67% at 12 months) and QALY (54% over 12 months) outcomes were low. Multiple imputation techniques were used to address potential biases regarding incomplete data. Results of the base-case (imputed) analysis and the complete-case analysis were comparable with regard to policy implications, although, inevitably, point estimates for incremental costs and incremental QALYs differed across the analyses. The additional between-imputation uncertainty associated with multiple imputation is captured when applying bootstrapping techniques to generate cost-utility planes and acceptability curves due to the use of all 25 000 replications (5000 from each imputed data set).
The feasibility and implementation of a stratifi ed management approach with matched treatment pathways is a necessary consideration. Training physiotherapists to use the prognostic screening tool and deliver the systematic targeted treatments incur costs due to the time commitments of trainers, trainees and mentors. Capacity constraints are also relevant, particularly with regard to the numbers of physiotherapists with the training and expertise to deliver the high-risk treatment package. However, expected cost savings attributable to the health service and society (through reduced healthcare consumption and fewer periods of work absence) are likely to provide considerable scope to accommodate such costs. In addition, evidence from observational data suggests that the proportion of low-risk patients (the risk group associated with the largest mean cost savings, see table 1) is greater in routine primary care than in a controlled trial environment. 42 Further research is ongoing to determine whether a similar stratifi ed approach is operable and sustainable within everyday primary care with general practitioners and physiotherapists. 43 
Concluding comments
Within each risk-defi ned subgroup of low back pain patients in primary care, a management approach combining prognostic screening and treatment targeting provides substantial economic benefi ts compared with current best practice. The magnitude of observed differences in health benefi ts and back pain-related costs suggests that the results are generalisable to other settings, although caution is advised when considering the external validity of any within-trial fi ndings. Research regarding the provision of targeted treatments for back pain is at an early stage and challenges exist with regard to the feasibility of implementation and effective delivery of this new management system. (27) 20 ( Contributors DGTW was the lead economist on the project, responsible for the design and analysis of the study and the original drafting of the report. SB provided additional health economic support. ML was the study statistician. JCH led the development of the Keele STarT Back Screening Tool and matched treatment pathways. EMH was the chief investigator and grant holder of the trial. All authors contributed to the interpretation of results and drafting of the report and have approved the fi nal version.
